Stoke Therapeutics, Inc.

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal

Current securities

1. SCHEDULE 13G - filed by BIOTECHNOLOGY VALUE FUND L P regarding Stoke Therapeutics, Inc.Sep 30, 2026
2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 25, 2026
3. SCHEDULE 13G/A - filed by Lynx1 Capital Management LP regarding Stoke Therapeutics, Inc.Aug 14, 2026
4. Other EventsAug 3, 2026
5. 424B5 filingAug 3, 2026